Developing low-carbon salbutamol MDI: assessment of relative bioavailability and pharmacodynamic relative potency of salbutamol MDI with propellant HFA-152a
Sebastian Moreira, Laura Clow, Emily Coles-Piper, Alison Donald, Christer Janson, Dave Singh, David Slade, Pankaj Tiwari, Stephen Weng, Maximilian Plank · 2026
Read Developing low-carbon salbutamol MDI: assessment of relative bioavailability and pharmacodynamic relative potency of salbutamol MDI with propellant HFA-152a by Sebastian Moreira, Laura Clow, Emily Coles-Piper, Alison Donald, Christer Janson, Dave Singh, David Slade, Pankaj Tiwari, Stephen Weng, Maximilian Plank (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/PMC13289305.txt.
Description
Sebastian Moreira and coauthors report 2026 phase I work on a lower-carbon salbutamol inhaler for asthma. Metered-dose inhalers use a propellant gas with strong warming effects, and the current gas, HFA-134a, adds to health care emissions. A new gas, HFA-152a, has about 90 percent lower warming potential and could replace it.
Two studies compared the new and old inhalers head to head. One tracked drug levels in 60 healthy adults after single doses, and the other tested airway response in 21 people with mild asthma using a methacholine challenge. Key drug level and potency measures fell inside preset equivalence ranges for both designs. No serious treatment-linked side effects appeared, supporting a cleaner inhaler that still works the same.
Catalog record
| CREATOR | Sebastian Moreira, Laura Clow, Emily Coles-Piper, Alison Donald, Christer Janson, Dave Singh, David Slade, Pankaj Tiwari, Stephen Weng, Maximilian Plank |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 30359 |
| LICENSE | https://creativecommons.org/licenses/by/4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |